Overview
The marketing authorisation for Patrex has not been renewed by the marketing authorisation holder and is now withdrawn.
Authorisation details
| Product details | |
|---|---|
| Name |
Patrex
|
| Agency product number |
EMEA/H/C/000204
|
| Active substance |
sildenafil
|
| International non-proprietary name (INN) or common name |
sildenafil
|
| Therapeutic area (MeSH) |
Erectile Dysfunction
|
| Anatomical therapeutic chemical (ATC) code |
G04BE03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Pfizer Limited
|
| Revision |
4
|
| Date of issue of marketing authorisation valid throughout the European Union |
15/09/1998
|
| Contact address |
Ramsgate Road
Sandwich Kent CT13 9NJ United Kingdom |
Product information
15/09/2003 Patrex - EMEA/H/C/000204 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Urologicals
Therapeutic indication
Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile
erection sufficient for satisfactory sexual performance.
In order for Patrex to be effective, sexual stimulation is required.
PATREX is not indicated for use by women.